nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemcitabine—kidney cancer—sarcoma	0.288	0.509	CtDrD
Gemcitabine—lung cancer—sarcoma	0.278	0.491	CtDrD
Gemcitabine—ABCC10—Vincristine—sarcoma	0.0798	0.326	CbGbCtD
Gemcitabine—ABCC10—Etoposide—sarcoma	0.0731	0.299	CbGbCtD
Gemcitabine—ABCC10—Doxorubicin—sarcoma	0.0499	0.204	CbGbCtD
Gemcitabine—ABCB1—Dactinomycin—sarcoma	0.0121	0.0494	CbGbCtD
Gemcitabine—ABCB1—Mitoxantrone—sarcoma	0.0108	0.0442	CbGbCtD
Gemcitabine—ABCB1—Vincristine—sarcoma	0.00744	0.0304	CbGbCtD
Gemcitabine—ABCB1—Etoposide—sarcoma	0.00681	0.0279	CbGbCtD
Gemcitabine—ABCB1—Doxorubicin—sarcoma	0.00465	0.019	CbGbCtD
Gemcitabine—RRM1—larynx—sarcoma	0.00256	0.043	CbGeAlD
Gemcitabine—POLE—mammary gland—sarcoma	0.00121	0.0204	CbGeAlD
Gemcitabine—POLA1—mammary gland—sarcoma	0.00104	0.0175	CbGeAlD
Gemcitabine—RRM2—mammary gland—sarcoma	0.000996	0.0168	CbGeAlD
Gemcitabine—POLD1—hematopoietic system—sarcoma	0.000986	0.0166	CbGeAlD
Gemcitabine—CDA—hematopoietic system—sarcoma	0.000885	0.0149	CbGeAlD
Gemcitabine—POLE—myometrium—sarcoma	0.000859	0.0144	CbGeAlD
Gemcitabine—POLD1—skin of body—sarcoma	0.000857	0.0144	CbGeAlD
Gemcitabine—RRM1—mammary gland—sarcoma	0.000828	0.0139	CbGeAlD
Gemcitabine—POLE—embryo—sarcoma	0.000826	0.0139	CbGeAlD
Gemcitabine—CMPK1—hematopoietic system—sarcoma	0.000787	0.0132	CbGeAlD
Gemcitabine—POLE—seminal vesicle—sarcoma	0.000776	0.0131	CbGeAlD
Gemcitabine—SLC28A1—liver—sarcoma	0.000767	0.0129	CbGeAlD
Gemcitabine—CMPK1—connective tissue—sarcoma	0.000757	0.0127	CbGeAlD
Gemcitabine—POLD1—uterus—sarcoma	0.000745	0.0125	CbGeAlD
Gemcitabine—POLA1—myometrium—sarcoma	0.00074	0.0125	CbGeAlD
Gemcitabine—POLE—hematopoietic system—sarcoma	0.000737	0.0124	CbGeAlD
Gemcitabine—POLD1—Removal of DNA patch containing abasic residue—SMUG1—sarcoma	0.000712	0.0519	CbGpPWpGaD
Gemcitabine—RRM2—myometrium—sarcoma	0.000707	0.0119	CbGeAlD
Gemcitabine—POLD1—lymphoid tissue—sarcoma	0.000694	0.0117	CbGeAlD
Gemcitabine—CMPK1—smooth muscle tissue—sarcoma	0.000693	0.0117	CbGeAlD
Gemcitabine—CMPK1—skin of body—sarcoma	0.000684	0.0115	CbGeAlD
Gemcitabine—RRM2—embryo—sarcoma	0.00068	0.0114	CbGeAlD
Gemcitabine—CDA—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000675	0.0492	CbGpPWpGaD
Gemcitabine—SLC29A1—mammary gland—sarcoma	0.000673	0.0113	CbGeAlD
Gemcitabine—POLA1—seminal vesicle—sarcoma	0.000669	0.0112	CbGeAlD
Gemcitabine—RRM2—Vinorelbine—Vincristine—sarcoma	0.000663	0.273	CbGdCrCtD
Gemcitabine—POLD1—Base Excision Repair—SMUG1—sarcoma	0.000651	0.0475	CbGpPWpGaD
Gemcitabine—POLA1—hematopoietic system—sarcoma	0.000635	0.0107	CbGeAlD
Gemcitabine—SLC29A2—cardiac atrium—sarcoma	0.000628	0.0106	CbGeAlD
Gemcitabine—POLA1—Vinblastine—Vincristine—sarcoma	0.000627	0.258	CbGdCrCtD
Gemcitabine—CDA—lymphoid tissue—sarcoma	0.000623	0.0105	CbGeAlD
Gemcitabine—RRM2—hematopoietic system—sarcoma	0.000607	0.0102	CbGeAlD
Gemcitabine—CMPK1—cardiac atrium—sarcoma	0.000597	0.0101	CbGeAlD
Gemcitabine—CMPK1—uterus—sarcoma	0.000594	0.01	CbGeAlD
Gemcitabine—RRM1—myometrium—sarcoma	0.000587	0.00988	CbGeAlD
Gemcitabine—CDA—tendon—sarcoma	0.000586	0.00986	CbGeAlD
Gemcitabine—SLC28A3—bone marrow—sarcoma	0.00058	0.00976	CbGeAlD
Gemcitabine—CDA—bone marrow—sarcoma	0.000567	0.00955	CbGeAlD
Gemcitabine—CMPK1—lymphoid tissue—sarcoma	0.000554	0.00932	CbGeAlD
Gemcitabine—SLC29A2—tendon—sarcoma	0.000547	0.00921	CbGeAlD
Gemcitabine—POLD1—testis—sarcoma	0.00054	0.00909	CbGeAlD
Gemcitabine—RRM1—seminal vesicle—sarcoma	0.000531	0.00893	CbGeAlD
Gemcitabine—RRM2—skin of body—sarcoma	0.000528	0.00888	CbGeAlD
Gemcitabine—POLE—lymphoid tissue—sarcoma	0.000519	0.00873	CbGeAlD
Gemcitabine—RRM1—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000512	0.0373	CbGpPWpGaD
Gemcitabine—POLD1—liver—sarcoma	0.000511	0.0086	CbGeAlD
Gemcitabine—CMPK1—bone marrow—sarcoma	0.000504	0.00849	CbGeAlD
Gemcitabine—RRM1—hematopoietic system—sarcoma	0.000504	0.00849	CbGeAlD
Gemcitabine—POLE—tendon—sarcoma	0.000488	0.00821	CbGeAlD
Gemcitabine—CDA—testis—sarcoma	0.000485	0.00816	CbGeAlD
Gemcitabine—SLC29A1—myometrium—sarcoma	0.000478	0.00804	CbGeAlD
Gemcitabine—POLE—bone marrow—sarcoma	0.000473	0.00795	CbGeAlD
Gemcitabine—SLC29A1—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000468	0.0341	CbGpPWpGaD
Gemcitabine—RRM2—uterus—sarcoma	0.000459	0.00772	CbGeAlD
Gemcitabine—CDA—liver—sarcoma	0.000458	0.00772	CbGeAlD
Gemcitabine—TYMS—hematopoietic system—sarcoma	0.000457	0.00769	CbGeAlD
Gemcitabine—DCK—myometrium—sarcoma	0.000456	0.00768	CbGeAlD
Gemcitabine—RRM1—smooth muscle tissue—sarcoma	0.000444	0.00747	CbGeAlD
Gemcitabine—TYMS—connective tissue—sarcoma	0.00044	0.00741	CbGeAlD
Gemcitabine—DCK—embryo—sarcoma	0.000439	0.00738	CbGeAlD
Gemcitabine—RRM1—skin of body—sarcoma	0.000438	0.00738	CbGeAlD
Gemcitabine—ABCC10—myometrium—sarcoma	0.000435	0.00731	CbGeAlD
Gemcitabine—CMPK1—testis—sarcoma	0.000431	0.00725	CbGeAlD
Gemcitabine—SLC29A2—liver—sarcoma	0.000429	0.00721	CbGeAlD
Gemcitabine—RRM2—lymphoid tissue—sarcoma	0.000427	0.00719	CbGeAlD
Gemcitabine—RRM2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000421	0.0307	CbGpPWpGaD
Gemcitabine—POLA1—tendon—sarcoma	0.000421	0.00708	CbGeAlD
Gemcitabine—DCK—seminal vesicle—sarcoma	0.000412	0.00694	CbGeAlD
Gemcitabine—SLC29A1—hematopoietic system—sarcoma	0.00041	0.0069	CbGeAlD
Gemcitabine—CMPK1—liver—sarcoma	0.000408	0.00686	CbGeAlD
Gemcitabine—POLA1—bone marrow—sarcoma	0.000407	0.00685	CbGeAlD
Gemcitabine—POLE—testis—sarcoma	0.000404	0.0068	CbGeAlD
Gemcitabine—TYMS—smooth muscle tissue—sarcoma	0.000403	0.00678	CbGeAlD
Gemcitabine—RRM2—tendon—sarcoma	0.000402	0.00676	CbGeAlD
Gemcitabine—TYMS—skin of body—sarcoma	0.000398	0.00669	CbGeAlD
Gemcitabine—SLC29A1—connective tissue—sarcoma	0.000395	0.00664	CbGeAlD
Gemcitabine—ABCC10—seminal vesicle—sarcoma	0.000393	0.00661	CbGeAlD
Gemcitabine—DCK—hematopoietic system—sarcoma	0.000392	0.00659	CbGeAlD
Gemcitabine—POLD1—lymph node—sarcoma	0.000392	0.00659	CbGeAlD
Gemcitabine—RRM2—bone marrow—sarcoma	0.000389	0.00655	CbGeAlD
Gemcitabine—RRM1—cardiac atrium—sarcoma	0.000383	0.00644	CbGeAlD
Gemcitabine—POLE—liver—sarcoma	0.000382	0.00643	CbGeAlD
Gemcitabine—RRM1—uterus—sarcoma	0.000381	0.00641	CbGeAlD
Gemcitabine—ABCC10—hematopoietic system—sarcoma	0.000373	0.00628	CbGeAlD
Gemcitabine—RRM1—lymphoid tissue—sarcoma	0.000355	0.00597	CbGeAlD
Gemcitabine—CDA—lymph node—sarcoma	0.000352	0.00592	CbGeAlD
Gemcitabine—POLA1—testis—sarcoma	0.000348	0.00586	CbGeAlD
Gemcitabine—RRM1—tendon—sarcoma	0.000334	0.00562	CbGeAlD
Gemcitabine—RRM2—testis—sarcoma	0.000333	0.0056	CbGeAlD
Gemcitabine—POLA1—liver—sarcoma	0.000329	0.00554	CbGeAlD
Gemcitabine—SLC29A2—lymph node—sarcoma	0.000329	0.00553	CbGeAlD
Gemcitabine—RRM1—bone marrow—sarcoma	0.000323	0.00544	CbGeAlD
Gemcitabine—TYMS—lymphoid tissue—sarcoma	0.000322	0.00542	CbGeAlD
Gemcitabine—RRM2—liver—sarcoma	0.000315	0.00529	CbGeAlD
Gemcitabine—CMPK1—lymph node—sarcoma	0.000312	0.00526	CbGeAlD
Gemcitabine—SLC29A1—cardiac atrium—sarcoma	0.000311	0.00524	CbGeAlD
Gemcitabine—SLC29A1—uterus—sarcoma	0.00031	0.00521	CbGeAlD
Gemcitabine—TYMS—tendon—sarcoma	0.000303	0.00509	CbGeAlD
Gemcitabine—DCK—cardiac atrium—sarcoma	0.000297	0.00501	CbGeAlD
Gemcitabine—DCK—uterus—sarcoma	0.000296	0.00498	CbGeAlD
Gemcitabine—TYMS—bone marrow—sarcoma	0.000293	0.00493	CbGeAlD
Gemcitabine—POLE—lymph node—sarcoma	0.000293	0.00493	CbGeAlD
Gemcitabine—SLC29A1—lymphoid tissue—sarcoma	0.000289	0.00486	CbGeAlD
Gemcitabine—ABCC10—cardiac atrium—sarcoma	0.000283	0.00477	CbGeAlD
Gemcitabine—TYMS—Vinorelbine—Vincristine—sarcoma	0.000283	0.117	CbGdCrCtD
Gemcitabine—TYMS—Podofilox—Etoposide—sarcoma	0.000283	0.117	CbGdCrCtD
Gemcitabine—ABCC10—uterus—sarcoma	0.000282	0.00474	CbGeAlD
Gemcitabine—RRM1—testis—sarcoma	0.000276	0.00465	CbGeAlD
Gemcitabine—TYMS—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000276	0.0201	CbGpPWpGaD
Gemcitabine—DCK—lymphoid tissue—sarcoma	0.000276	0.00464	CbGeAlD
Gemcitabine—SLC29A1—tendon—sarcoma	0.000271	0.00457	CbGeAlD
Gemcitabine—SLC29A1—bone marrow—sarcoma	0.000263	0.00442	CbGeAlD
Gemcitabine—ABCC10—lymphoid tissue—sarcoma	0.000263	0.00442	CbGeAlD
Gemcitabine—RRM1—liver—sarcoma	0.000261	0.0044	CbGeAlD
Gemcitabine—DCK—tendon—sarcoma	0.000259	0.00436	CbGeAlD
Gemcitabine—POLD1—Chromosome Maintenance—NPM1—sarcoma	0.000259	0.0189	CbGpPWpGaD
Gemcitabine—POLA1—lymph node—sarcoma	0.000252	0.00425	CbGeAlD
Gemcitabine—POLD1—S Phase—STAG1—sarcoma	0.000252	0.0184	CbGpPWpGaD
Gemcitabine—DCK—bone marrow—sarcoma	0.000251	0.00423	CbGeAlD
Gemcitabine—TYMS—testis—sarcoma	0.000251	0.00422	CbGeAlD
Gemcitabine—POLE—Chromosome Maintenance—NPM1—sarcoma	0.00025	0.0183	CbGpPWpGaD
Gemcitabine—ABCC10—tendon—sarcoma	0.000247	0.00416	CbGeAlD
Gemcitabine—POLE—S Phase—STAG1—sarcoma	0.000243	0.0177	CbGpPWpGaD
Gemcitabine—RRM2—lymph node—sarcoma	0.000241	0.00406	CbGeAlD
Gemcitabine—ABCC10—bone marrow—sarcoma	0.000239	0.00403	CbGeAlD
Gemcitabine—TYMS—liver—sarcoma	0.000237	0.00399	CbGeAlD
Gemcitabine—SLC29A1—testis—sarcoma	0.000225	0.00378	CbGeAlD
Gemcitabine—DCK—testis—sarcoma	0.000215	0.00361	CbGeAlD
Gemcitabine—SLC29A1—liver—sarcoma	0.000212	0.00357	CbGeAlD
Gemcitabine—ABCC10—testis—sarcoma	0.000205	0.00344	CbGeAlD
Gemcitabine—DCK—liver—sarcoma	0.000203	0.00342	CbGeAlD
Gemcitabine—RRM1—lymph node—sarcoma	0.0002	0.00337	CbGeAlD
Gemcitabine—DCK—Doxorubicin—Epirubicin—sarcoma	0.000196	0.0807	CbGdCrCtD
Gemcitabine—TYMS—Vinblastine—Vincristine—sarcoma	0.000195	0.0802	CbGdCrCtD
Gemcitabine—ABCC10—liver—sarcoma	0.000193	0.00325	CbGeAlD
Gemcitabine—TYMS—lymph node—sarcoma	0.000182	0.00306	CbGeAlD
Gemcitabine—DCK—Epirubicin—Doxorubicin—sarcoma	0.000181	0.0747	CbGdCrCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000179	0.0131	CbGpPWpGaD
Gemcitabine—CDA—Fluoropyrimidine Activity—TP53—sarcoma	0.000179	0.0131	CbGpPWpGaD
Gemcitabine—POLA1—Chromosome Maintenance—NPM1—sarcoma	0.000178	0.013	CbGpPWpGaD
Gemcitabine—POLA1—S Phase—STAG1—sarcoma	0.000173	0.0126	CbGpPWpGaD
Gemcitabine—SLC29A1—lymph node—sarcoma	0.000163	0.00274	CbGeAlD
Gemcitabine—POLD1—DNA Repair—SMUG1—sarcoma	0.000156	0.0114	CbGpPWpGaD
Gemcitabine—DCK—lymph node—sarcoma	0.000156	0.00262	CbGeAlD
Gemcitabine—POLE—DNA Repair—SMUG1—sarcoma	0.000151	0.011	CbGpPWpGaD
Gemcitabine—ABCC10—lymph node—sarcoma	0.000148	0.00249	CbGeAlD
Gemcitabine—RRM1—Fluoropyrimidine Activity—TP53—sarcoma	0.000136	0.00991	CbGpPWpGaD
Gemcitabine—POLE—G1 to S cell cycle control—CREB1—sarcoma	0.000127	0.00925	CbGpPWpGaD
Gemcitabine—ABCB1—myometrium—sarcoma	0.000126	0.00211	CbGeAlD
Gemcitabine—SLC29A1—Fluoropyrimidine Activity—TP53—sarcoma	0.000124	0.00906	CbGpPWpGaD
Gemcitabine—ABCB1—embryo—sarcoma	0.000121	0.00203	CbGeAlD
Gemcitabine—ABCB1—seminal vesicle—sarcoma	0.000113	0.00191	CbGeAlD
Gemcitabine—RRM2—Fluoropyrimidine Activity—TP53—sarcoma	0.000112	0.00816	CbGpPWpGaD
Gemcitabine—POLE—Mitotic M-M/G1 phases—STAG1—sarcoma	0.000111	0.00808	CbGpPWpGaD
Gemcitabine—RRM1—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000109	0.00795	CbGpPWpGaD
Gemcitabine—ABCB1—hematopoietic system—sarcoma	0.000108	0.00181	CbGeAlD
Gemcitabine—POLE—G1 to S cell cycle control—MDM2—sarcoma	0.000105	0.00765	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000101	0.00737	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	9.68e-05	0.00706	CbGpPWpGaD
Gemcitabine—Cardiac failure congestive—Doxorubicin—sarcoma	9.56e-05	0.000838	CcSEcCtD
Gemcitabine—Hyperhidrosis—Mitoxantrone—sarcoma	9.55e-05	0.000837	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	9.52e-05	0.00694	CbGpPWpGaD
Gemcitabine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	9.5e-05	0.00692	CbGpPWpGaD
Gemcitabine—Hypotension—Vincristine—sarcoma	9.48e-05	0.000831	CcSEcCtD
Gemcitabine—Feeling abnormal—Thiotepa—sarcoma	9.43e-05	0.000826	CcSEcCtD
Gemcitabine—Anorexia—Mitoxantrone—sarcoma	9.42e-05	0.000825	CcSEcCtD
Gemcitabine—Feeling abnormal—Dactinomycin—sarcoma	9.36e-05	0.00082	CcSEcCtD
Gemcitabine—Ill-defined disorder—Etoposide—sarcoma	9.34e-05	0.000819	CcSEcCtD
Gemcitabine—Anaemia—Etoposide—sarcoma	9.31e-05	0.000816	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Vincristine—sarcoma	9.24e-05	0.00081	CcSEcCtD
Gemcitabine—Hypotension—Mitoxantrone—sarcoma	9.23e-05	0.000809	CcSEcCtD
Gemcitabine—Insomnia—Vincristine—sarcoma	9.17e-05	0.000804	CcSEcCtD
Gemcitabine—POLE—G1 to S cell cycle control—CCND1—sarcoma	9.14e-05	0.00667	CbGpPWpGaD
Gemcitabine—Renal impairment—Doxorubicin—sarcoma	9.11e-05	0.000798	CcSEcCtD
Gemcitabine—Paraesthesia—Vincristine—sarcoma	9.11e-05	0.000798	CcSEcCtD
Gemcitabine—Malaise—Etoposide—sarcoma	9.08e-05	0.000796	CcSEcCtD
Gemcitabine—Dermatitis bullous—Doxorubicin—sarcoma	9.07e-05	0.000795	CcSEcCtD
Gemcitabine—Face oedema—Epirubicin—sarcoma	9.05e-05	0.000793	CcSEcCtD
Gemcitabine—Body temperature increased—Thiotepa—sarcoma	9.04e-05	0.000792	CcSEcCtD
Gemcitabine—Leukopenia—Etoposide—sarcoma	9.01e-05	0.00079	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Mitoxantrone—sarcoma	9e-05	0.000789	CcSEcCtD
Gemcitabine—RRM2—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	8.98e-05	0.00655	CbGpPWpGaD
Gemcitabine—Body temperature increased—Dactinomycin—sarcoma	8.98e-05	0.000787	CcSEcCtD
Gemcitabine—Anaphylactoid reaction—Doxorubicin—sarcoma	8.96e-05	0.000785	CcSEcCtD
Gemcitabine—Cardiac failure—Doxorubicin—sarcoma	8.89e-05	0.000779	CcSEcCtD
Gemcitabine—Paraesthesia—Mitoxantrone—sarcoma	8.87e-05	0.000777	CcSEcCtD
Gemcitabine—Cerebrovascular accident—Doxorubicin—sarcoma	8.85e-05	0.000775	CcSEcCtD
Gemcitabine—Decreased appetite—Vincristine—sarcoma	8.82e-05	0.000773	CcSEcCtD
Gemcitabine—Dyspnoea—Mitoxantrone—sarcoma	8.81e-05	0.000772	CcSEcCtD
Gemcitabine—Cough—Etoposide—sarcoma	8.79e-05	0.00077	CcSEcCtD
Gemcitabine—Somnolence—Mitoxantrone—sarcoma	8.78e-05	0.00077	CcSEcCtD
Gemcitabine—Blood creatinine increased—Epirubicin—sarcoma	8.78e-05	0.000769	CcSEcCtD
Gemcitabine—RRM1—E2F transcription factor network—MYC—sarcoma	8.76e-05	0.00639	CbGpPWpGaD
Gemcitabine—Gastrointestinal disorder—Vincristine—sarcoma	8.76e-05	0.000767	CcSEcCtD
Gemcitabine—Fatigue—Vincristine—sarcoma	8.75e-05	0.000766	CcSEcCtD
Gemcitabine—Hypertension—Etoposide—sarcoma	8.69e-05	0.000762	CcSEcCtD
Gemcitabine—Constipation—Vincristine—sarcoma	8.67e-05	0.00076	CcSEcCtD
Gemcitabine—Pain—Vincristine—sarcoma	8.67e-05	0.00076	CcSEcCtD
Gemcitabine—Liver function test abnormal—Epirubicin—sarcoma	8.65e-05	0.000758	CcSEcCtD
Gemcitabine—RRM2—Cell Cycle, Mitotic—STAG1—sarcoma	8.63e-05	0.00629	CbGpPWpGaD
Gemcitabine—POLE—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	8.62e-05	0.00628	CbGpPWpGaD
Gemcitabine—Decreased appetite—Mitoxantrone—sarcoma	8.59e-05	0.000753	CcSEcCtD
Gemcitabine—POLD1—Cell Cycle, Mitotic—STAG1—sarcoma	8.58e-05	0.00625	CbGpPWpGaD
Gemcitabine—Chest pain—Etoposide—sarcoma	8.57e-05	0.000751	CcSEcCtD
Gemcitabine—Hypokalaemia—Epirubicin—sarcoma	8.53e-05	0.000747	CcSEcCtD
Gemcitabine—Fatigue—Mitoxantrone—sarcoma	8.52e-05	0.000746	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	8.51e-05	0.000746	CcSEcCtD
Gemcitabine—Discomfort—Etoposide—sarcoma	8.47e-05	0.000742	CcSEcCtD
Gemcitabine—Pain—Mitoxantrone—sarcoma	8.45e-05	0.00074	CcSEcCtD
Gemcitabine—Constipation—Mitoxantrone—sarcoma	8.45e-05	0.00074	CcSEcCtD
Gemcitabine—Toxic epidermal necrolysis—Epirubicin—sarcoma	8.44e-05	0.00074	CcSEcCtD
Gemcitabine—Aspartate aminotransferase increased—Epirubicin—sarcoma	8.44e-05	0.00074	CcSEcCtD
Gemcitabine—DCK—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	8.39e-05	0.00612	CbGpPWpGaD
Gemcitabine—Face oedema—Doxorubicin—sarcoma	8.37e-05	0.000734	CcSEcCtD
Gemcitabine—POLE—Cell Cycle, Mitotic—STAG1—sarcoma	8.28e-05	0.00604	CbGpPWpGaD
Gemcitabine—Alanine aminotransferase increased—Epirubicin—sarcoma	8.27e-05	0.000724	CcSEcCtD
Gemcitabine—Anaphylactic shock—Etoposide—sarcoma	8.22e-05	0.00072	CcSEcCtD
Gemcitabine—Asthenia—Thiotepa—sarcoma	8.21e-05	0.000719	CcSEcCtD
Gemcitabine—Infection—Etoposide—sarcoma	8.16e-05	0.000715	CcSEcCtD
Gemcitabine—Asthenia—Dactinomycin—sarcoma	8.15e-05	0.000714	CcSEcCtD
Gemcitabine—Feeling abnormal—Mitoxantrone—sarcoma	8.14e-05	0.000713	CcSEcCtD
Gemcitabine—ABCB1—uterus—sarcoma	8.14e-05	0.00137	CbGeAlD
Gemcitabine—Blood creatinine increased—Doxorubicin—sarcoma	8.12e-05	0.000712	CcSEcCtD
Gemcitabine—Influenza—Epirubicin—sarcoma	8.1e-05	0.00071	CcSEcCtD
Gemcitabine—Pruritus—Thiotepa—sarcoma	8.09e-05	0.000709	CcSEcCtD
Gemcitabine—Thrombocytopenia—Etoposide—sarcoma	8.05e-05	0.000705	CcSEcCtD
Gemcitabine—Body temperature increased—Vincristine—sarcoma	8.02e-05	0.000703	CcSEcCtD
Gemcitabine—Liver function test abnormal—Doxorubicin—sarcoma	8.01e-05	0.000702	CcSEcCtD
Gemcitabine—Skin disorder—Etoposide—sarcoma	7.98e-05	0.000699	CcSEcCtD
Gemcitabine—Hyperhidrosis—Etoposide—sarcoma	7.94e-05	0.000696	CcSEcCtD
Gemcitabine—Hypokalaemia—Doxorubicin—sarcoma	7.89e-05	0.000692	CcSEcCtD
Gemcitabine—POLA1—Mitotic M-M/G1 phases—STAG1—sarcoma	7.89e-05	0.00575	CbGpPWpGaD
Gemcitabine—Anorexia—Etoposide—sarcoma	7.83e-05	0.000686	CcSEcCtD
Gemcitabine—Diarrhoea—Thiotepa—sarcoma	7.83e-05	0.000686	CcSEcCtD
Gemcitabine—RRM2—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	7.82e-05	0.0057	CbGpPWpGaD
Gemcitabine—Body temperature increased—Mitoxantrone—sarcoma	7.81e-05	0.000684	CcSEcCtD
Gemcitabine—Aspartate aminotransferase increased—Doxorubicin—sarcoma	7.81e-05	0.000684	CcSEcCtD
Gemcitabine—Toxic epidermal necrolysis—Doxorubicin—sarcoma	7.81e-05	0.000684	CcSEcCtD
Gemcitabine—Diarrhoea—Dactinomycin—sarcoma	7.77e-05	0.000681	CcSEcCtD
Gemcitabine—RRM2—Cell Cycle—STAG1—sarcoma	7.71e-05	0.00563	CbGpPWpGaD
Gemcitabine—Pancytopenia—Epirubicin—sarcoma	7.69e-05	0.000674	CcSEcCtD
Gemcitabine—Hypotension—Etoposide—sarcoma	7.68e-05	0.000673	CcSEcCtD
Gemcitabine—POLD1—Cell Cycle—STAG1—sarcoma	7.67e-05	0.00559	CbGpPWpGaD
Gemcitabine—Alanine aminotransferase increased—Doxorubicin—sarcoma	7.65e-05	0.00067	CcSEcCtD
Gemcitabine—RRM1—Retinoblastoma (RB) in Cancer—MYC—sarcoma	7.62e-05	0.00555	CbGpPWpGaD
Gemcitabine—ABCB1—lymphoid tissue—sarcoma	7.59e-05	0.00128	CbGeAlD
Gemcitabine—Neutropenia—Epirubicin—sarcoma	7.57e-05	0.000664	CcSEcCtD
Gemcitabine—POLE—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	7.51e-05	0.00547	CbGpPWpGaD
Gemcitabine—Influenza—Doxorubicin—sarcoma	7.49e-05	0.000657	CcSEcCtD
Gemcitabine—POLE—Cell Cycle—STAG1—sarcoma	7.41e-05	0.0054	CbGpPWpGaD
Gemcitabine—Paraesthesia—Etoposide—sarcoma	7.38e-05	0.000647	CcSEcCtD
Gemcitabine—POLE—G1 to S cell cycle control—MYC—sarcoma	7.33e-05	0.00535	CbGpPWpGaD
Gemcitabine—TYMS—Fluoropyrimidine Activity—TP53—sarcoma	7.33e-05	0.00535	CbGpPWpGaD
Gemcitabine—Dyspnoea—Etoposide—sarcoma	7.33e-05	0.000642	CcSEcCtD
Gemcitabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	7.31e-05	0.00533	CbGpPWpGaD
Gemcitabine—Hyperglycaemia—Epirubicin—sarcoma	7.31e-05	0.00064	CcSEcCtD
Gemcitabine—Somnolence—Etoposide—sarcoma	7.31e-05	0.00064	CcSEcCtD
Gemcitabine—Asthenia—Vincristine—sarcoma	7.28e-05	0.000638	CcSEcCtD
Gemcitabine—Vomiting—Thiotepa—sarcoma	7.27e-05	0.000637	CcSEcCtD
Gemcitabine—Pneumonia—Epirubicin—sarcoma	7.26e-05	0.000637	CcSEcCtD
Gemcitabine—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	7.23e-05	0.00528	CbGpPWpGaD
Gemcitabine—Vomiting—Dactinomycin—sarcoma	7.22e-05	0.000633	CcSEcCtD
Gemcitabine—RRM2—E2F transcription factor network—MYC—sarcoma	7.22e-05	0.00526	CbGpPWpGaD
Gemcitabine—Rash—Thiotepa—sarcoma	7.21e-05	0.000632	CcSEcCtD
Gemcitabine—Dermatitis—Thiotepa—sarcoma	7.21e-05	0.000631	CcSEcCtD
Gemcitabine—Headache—Thiotepa—sarcoma	7.17e-05	0.000628	CcSEcCtD
Gemcitabine—Stevens-Johnson syndrome—Epirubicin—sarcoma	7.16e-05	0.000627	CcSEcCtD
Gemcitabine—Rash—Dactinomycin—sarcoma	7.16e-05	0.000627	CcSEcCtD
Gemcitabine—Decreased appetite—Etoposide—sarcoma	7.14e-05	0.000626	CcSEcCtD
Gemcitabine—Pancytopenia—Doxorubicin—sarcoma	7.12e-05	0.000624	CcSEcCtD
Gemcitabine—Renal failure—Epirubicin—sarcoma	7.1e-05	0.000622	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Etoposide—sarcoma	7.09e-05	0.000622	CcSEcCtD
Gemcitabine—Asthenia—Mitoxantrone—sarcoma	7.09e-05	0.000621	CcSEcCtD
Gemcitabine—Fatigue—Etoposide—sarcoma	7.08e-05	0.000621	CcSEcCtD
Gemcitabine—Neuropathy peripheral—Epirubicin—sarcoma	7.08e-05	0.00062	CcSEcCtD
Gemcitabine—Stomatitis—Epirubicin—sarcoma	7.04e-05	0.000617	CcSEcCtD
Gemcitabine—Constipation—Etoposide—sarcoma	7.03e-05	0.000616	CcSEcCtD
Gemcitabine—Pain—Etoposide—sarcoma	7.03e-05	0.000616	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	7.02e-05	0.00512	CbGpPWpGaD
Gemcitabine—Neutropenia—Doxorubicin—sarcoma	7.01e-05	0.000614	CcSEcCtD
Gemcitabine—Diarrhoea—Vincristine—sarcoma	6.94e-05	0.000608	CcSEcCtD
Gemcitabine—Sweating—Epirubicin—sarcoma	6.92e-05	0.000607	CcSEcCtD
Gemcitabine—ABCB1—bone marrow—sarcoma	6.91e-05	0.00116	CbGeAlD
Gemcitabine—Haematuria—Epirubicin—sarcoma	6.89e-05	0.000603	CcSEcCtD
Gemcitabine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	6.86e-05	0.00501	CbGpPWpGaD
Gemcitabine—Hepatobiliary disease—Epirubicin—sarcoma	6.83e-05	0.000599	CcSEcCtD
Gemcitabine—Nausea—Thiotepa—sarcoma	6.8e-05	0.000595	CcSEcCtD
Gemcitabine—Feeling abnormal—Etoposide—sarcoma	6.77e-05	0.000593	CcSEcCtD
Gemcitabine—Hyperglycaemia—Doxorubicin—sarcoma	6.76e-05	0.000592	CcSEcCtD
Gemcitabine—Diarrhoea—Mitoxantrone—sarcoma	6.76e-05	0.000592	CcSEcCtD
Gemcitabine—Nausea—Dactinomycin—sarcoma	6.74e-05	0.000591	CcSEcCtD
Gemcitabine—Agranulocytosis—Epirubicin—sarcoma	6.74e-05	0.000591	CcSEcCtD
Gemcitabine—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	6.73e-05	0.00491	CbGpPWpGaD
Gemcitabine—Pneumonia—Doxorubicin—sarcoma	6.72e-05	0.000589	CcSEcCtD
Gemcitabine—Stevens-Johnson syndrome—Doxorubicin—sarcoma	6.63e-05	0.000581	CcSEcCtD
Gemcitabine—RRM2—Cell Cycle—NPM1—sarcoma	6.62e-05	0.00483	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—NPM1—sarcoma	6.58e-05	0.0048	CbGpPWpGaD
Gemcitabine—Renal failure—Doxorubicin—sarcoma	6.57e-05	0.000576	CcSEcCtD
Gemcitabine—Neuropathy peripheral—Doxorubicin—sarcoma	6.55e-05	0.000574	CcSEcCtD
Gemcitabine—Haemoglobin—Epirubicin—sarcoma	6.52e-05	0.000571	CcSEcCtD
Gemcitabine—Stomatitis—Doxorubicin—sarcoma	6.51e-05	0.000571	CcSEcCtD
Gemcitabine—Rhinitis—Epirubicin—sarcoma	6.5e-05	0.00057	CcSEcCtD
Gemcitabine—Body temperature increased—Etoposide—sarcoma	6.5e-05	0.000569	CcSEcCtD
Gemcitabine—Haemorrhage—Epirubicin—sarcoma	6.48e-05	0.000568	CcSEcCtD
Gemcitabine—Vomiting—Vincristine—sarcoma	6.45e-05	0.000565	CcSEcCtD
Gemcitabine—Pharyngitis—Epirubicin—sarcoma	6.43e-05	0.000564	CcSEcCtD
Gemcitabine—Sweating—Doxorubicin—sarcoma	6.41e-05	0.000561	CcSEcCtD
Gemcitabine—Urinary tract disorder—Epirubicin—sarcoma	6.4e-05	0.000561	CcSEcCtD
Gemcitabine—Rash—Vincristine—sarcoma	6.4e-05	0.00056	CcSEcCtD
Gemcitabine—Dermatitis—Vincristine—sarcoma	6.39e-05	0.00056	CcSEcCtD
Gemcitabine—CMPK1—Metabolism—ENO2—sarcoma	6.39e-05	0.00466	CbGpPWpGaD
Gemcitabine—Oedema peripheral—Epirubicin—sarcoma	6.39e-05	0.00056	CcSEcCtD
Gemcitabine—Haematuria—Doxorubicin—sarcoma	6.37e-05	0.000558	CcSEcCtD
Gemcitabine—Connective tissue disorder—Epirubicin—sarcoma	6.37e-05	0.000558	CcSEcCtD
Gemcitabine—Urethral disorder—Epirubicin—sarcoma	6.36e-05	0.000557	CcSEcCtD
Gemcitabine—Headache—Vincristine—sarcoma	6.35e-05	0.000557	CcSEcCtD
Gemcitabine—POLE—Cell Cycle—NPM1—sarcoma	6.35e-05	0.00463	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—HBA1—sarcoma	6.35e-05	0.00463	CbGpPWpGaD
Gemcitabine—Hepatobiliary disease—Doxorubicin—sarcoma	6.32e-05	0.000554	CcSEcCtD
Gemcitabine—Vomiting—Mitoxantrone—sarcoma	6.28e-05	0.00055	CcSEcCtD
Gemcitabine—RRM2—Retinoblastoma (RB) in Cancer—MYC—sarcoma	6.27e-05	0.00457	CbGpPWpGaD
Gemcitabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—sarcoma	6.26e-05	0.00456	CbGpPWpGaD
Gemcitabine—Agranulocytosis—Doxorubicin—sarcoma	6.24e-05	0.000546	CcSEcCtD
Gemcitabine—Rash—Mitoxantrone—sarcoma	6.23e-05	0.000546	CcSEcCtD
Gemcitabine—Dermatitis—Mitoxantrone—sarcoma	6.22e-05	0.000545	CcSEcCtD
Gemcitabine—Headache—Mitoxantrone—sarcoma	6.19e-05	0.000542	CcSEcCtD
Gemcitabine—POLA1—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	6.14e-05	0.00448	CbGpPWpGaD
Gemcitabine—Erythema multiforme—Epirubicin—sarcoma	6.13e-05	0.000537	CcSEcCtD
Gemcitabine—Haemoglobin—Doxorubicin—sarcoma	6.03e-05	0.000528	CcSEcCtD
Gemcitabine—Nausea—Vincristine—sarcoma	6.03e-05	0.000528	CcSEcCtD
Gemcitabine—POLE—G1 to S cell cycle control—TP53—sarcoma	6.02e-05	0.00439	CbGpPWpGaD
Gemcitabine—POLE—Retinoblastoma (RB) in Cancer—MYC—sarcoma	6.02e-05	0.00439	CbGpPWpGaD
Gemcitabine—Cardiac disorder—Epirubicin—sarcoma	6.02e-05	0.000527	CcSEcCtD
Gemcitabine—Rhinitis—Doxorubicin—sarcoma	6.01e-05	0.000527	CcSEcCtD
Gemcitabine—Haemorrhage—Doxorubicin—sarcoma	6e-05	0.000526	CcSEcCtD
Gemcitabine—Pharyngitis—Doxorubicin—sarcoma	5.95e-05	0.000522	CcSEcCtD
Gemcitabine—Urinary tract disorder—Doxorubicin—sarcoma	5.92e-05	0.000519	CcSEcCtD
Gemcitabine—Oedema peripheral—Doxorubicin—sarcoma	5.91e-05	0.000518	CcSEcCtD
Gemcitabine—ABCB1—testis—sarcoma	5.91e-05	0.000994	CbGeAlD
Gemcitabine—POLA1—Cell Cycle, Mitotic—STAG1—sarcoma	5.9e-05	0.0043	CbGpPWpGaD
Gemcitabine—Asthenia—Etoposide—sarcoma	5.9e-05	0.000517	CcSEcCtD
Gemcitabine—Connective tissue disorder—Doxorubicin—sarcoma	5.9e-05	0.000517	CcSEcCtD
Gemcitabine—POLD1—S Phase—CCND1—sarcoma	5.89e-05	0.0043	CbGpPWpGaD
Gemcitabine—TYMS—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	5.88e-05	0.00429	CbGpPWpGaD
Gemcitabine—Angiopathy—Epirubicin—sarcoma	5.88e-05	0.000515	CcSEcCtD
Gemcitabine—Urethral disorder—Doxorubicin—sarcoma	5.88e-05	0.000515	CcSEcCtD
Gemcitabine—Nausea—Mitoxantrone—sarcoma	5.87e-05	0.000514	CcSEcCtD
Gemcitabine—DCK—Retinoblastoma (RB) in Cancer—MYC—sarcoma	5.86e-05	0.00427	CbGpPWpGaD
Gemcitabine—Immune system disorder—Epirubicin—sarcoma	5.86e-05	0.000513	CcSEcCtD
Gemcitabine—Mediastinal disorder—Epirubicin—sarcoma	5.84e-05	0.000512	CcSEcCtD
Gemcitabine—Chills—Epirubicin—sarcoma	5.82e-05	0.00051	CcSEcCtD
Gemcitabine—Pruritus—Etoposide—sarcoma	5.81e-05	0.000509	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	5.81e-05	0.00424	CbGpPWpGaD
Gemcitabine—Arrhythmia—Epirubicin—sarcoma	5.79e-05	0.000508	CcSEcCtD
Gemcitabine—Alopecia—Epirubicin—sarcoma	5.73e-05	0.000502	CcSEcCtD
Gemcitabine—POLE—S Phase—CCND1—sarcoma	5.69e-05	0.00415	CbGpPWpGaD
Gemcitabine—Erythema multiforme—Doxorubicin—sarcoma	5.67e-05	0.000497	CcSEcCtD
Gemcitabine—TYMS—Cell Cycle, Mitotic—STAG1—sarcoma	5.65e-05	0.00412	CbGpPWpGaD
Gemcitabine—Erythema—Epirubicin—sarcoma	5.64e-05	0.000495	CcSEcCtD
Gemcitabine—Diarrhoea—Etoposide—sarcoma	5.62e-05	0.000493	CcSEcCtD
Gemcitabine—ABCB1—liver—sarcoma	5.58e-05	0.000939	CbGeAlD
Gemcitabine—Cardiac disorder—Doxorubicin—sarcoma	5.57e-05	0.000488	CcSEcCtD
Gemcitabine—RRM2—Mitotic G1-G1/S phases—CCND1—sarcoma	5.5e-05	0.00401	CbGpPWpGaD
Gemcitabine—Back pain—Epirubicin—sarcoma	5.46e-05	0.000478	CcSEcCtD
Gemcitabine—Angiopathy—Doxorubicin—sarcoma	5.44e-05	0.000477	CcSEcCtD
Gemcitabine—CMPK1—Metabolism—PLCG1—sarcoma	5.42e-05	0.00395	CbGpPWpGaD
Gemcitabine—Immune system disorder—Doxorubicin—sarcoma	5.42e-05	0.000475	CcSEcCtD
Gemcitabine—Mediastinal disorder—Doxorubicin—sarcoma	5.41e-05	0.000474	CcSEcCtD
Gemcitabine—Chills—Doxorubicin—sarcoma	5.38e-05	0.000472	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	5.36e-05	0.00391	CbGpPWpGaD
Gemcitabine—Arrhythmia—Doxorubicin—sarcoma	5.36e-05	0.00047	CcSEcCtD
Gemcitabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	5.35e-05	0.0039	CbGpPWpGaD
Gemcitabine—Alopecia—Doxorubicin—sarcoma	5.3e-05	0.000465	CcSEcCtD
Gemcitabine—POLE—Mitotic G1-G1/S phases—CCND1—sarcoma	5.28e-05	0.00385	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—STAG1—sarcoma	5.28e-05	0.00385	CbGpPWpGaD
Gemcitabine—RRM2—G1/S Transition—MYC—sarcoma	5.24e-05	0.00382	CbGpPWpGaD
Gemcitabine—Ill-defined disorder—Epirubicin—sarcoma	5.24e-05	0.000459	CcSEcCtD
Gemcitabine—Vomiting—Etoposide—sarcoma	5.22e-05	0.000458	CcSEcCtD
Gemcitabine—Erythema—Doxorubicin—sarcoma	5.22e-05	0.000458	CcSEcCtD
Gemcitabine—Anaemia—Epirubicin—sarcoma	5.22e-05	0.000457	CcSEcCtD
Gemcitabine—Rash—Etoposide—sarcoma	5.18e-05	0.000454	CcSEcCtD
Gemcitabine—Dermatitis—Etoposide—sarcoma	5.18e-05	0.000454	CcSEcCtD
Gemcitabine—RRM2—Retinoblastoma (RB) in Cancer—TP53—sarcoma	5.15e-05	0.00376	CbGpPWpGaD
Gemcitabine—Headache—Etoposide—sarcoma	5.15e-05	0.000451	CcSEcCtD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	5.14e-05	0.00374	CbGpPWpGaD
Gemcitabine—TYMS—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	5.12e-05	0.00374	CbGpPWpGaD
Gemcitabine—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	5.11e-05	0.00373	CbGpPWpGaD
Gemcitabine—Malaise—Epirubicin—sarcoma	5.09e-05	0.000446	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	5.06e-05	0.00369	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—STAG1—sarcoma	5.06e-05	0.00369	CbGpPWpGaD
Gemcitabine—Leukopenia—Epirubicin—sarcoma	5.05e-05	0.000443	CcSEcCtD
Gemcitabine—Back pain—Doxorubicin—sarcoma	5.05e-05	0.000443	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	5.05e-05	0.00368	CbGpPWpGaD
Gemcitabine—POLE—G1/S Transition—MYC—sarcoma	5.03e-05	0.00367	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	5.01e-05	0.00366	CbGpPWpGaD
Gemcitabine—POLE—Retinoblastoma (RB) in Cancer—TP53—sarcoma	4.94e-05	0.00361	CbGpPWpGaD
Gemcitabine—POLA1—E2F transcription factor network—MYC—sarcoma	4.94e-05	0.0036	CbGpPWpGaD
Gemcitabine—Cough—Epirubicin—sarcoma	4.93e-05	0.000432	CcSEcCtD
Gemcitabine—Nausea—Etoposide—sarcoma	4.88e-05	0.000428	CcSEcCtD
Gemcitabine—Hypertension—Epirubicin—sarcoma	4.87e-05	0.000427	CcSEcCtD
Gemcitabine—Ill-defined disorder—Doxorubicin—sarcoma	4.85e-05	0.000425	CcSEcCtD
Gemcitabine—Anaemia—Doxorubicin—sarcoma	4.83e-05	0.000423	CcSEcCtD
Gemcitabine—DCK—Retinoblastoma (RB) in Cancer—TP53—sarcoma	4.81e-05	0.00351	CbGpPWpGaD
Gemcitabine—Chest pain—Epirubicin—sarcoma	4.81e-05	0.000421	CcSEcCtD
Gemcitabine—Arthralgia—Epirubicin—sarcoma	4.81e-05	0.000421	CcSEcCtD
Gemcitabine—Myalgia—Epirubicin—sarcoma	4.81e-05	0.000421	CcSEcCtD
Gemcitabine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	4.78e-05	0.00349	CbGpPWpGaD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.77e-05	0.000418	CcSEcCtD
Gemcitabine—Discomfort—Epirubicin—sarcoma	4.75e-05	0.000416	CcSEcCtD
Gemcitabine—TYMS—E2F transcription factor network—MYC—sarcoma	4.73e-05	0.00345	CbGpPWpGaD
Gemcitabine—POLD1—S Phase—MYC—sarcoma	4.73e-05	0.00345	CbGpPWpGaD
Gemcitabine—Malaise—Doxorubicin—sarcoma	4.71e-05	0.000413	CcSEcCtD
Gemcitabine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	4.71e-05	0.00343	CbGpPWpGaD
Gemcitabine—Leukopenia—Doxorubicin—sarcoma	4.67e-05	0.00041	CcSEcCtD
Gemcitabine—Oedema—Epirubicin—sarcoma	4.61e-05	0.000404	CcSEcCtD
Gemcitabine—Anaphylactic shock—Epirubicin—sarcoma	4.61e-05	0.000404	CcSEcCtD
Gemcitabine—Infection—Epirubicin—sarcoma	4.58e-05	0.000401	CcSEcCtD
Gemcitabine—POLE—S Phase—MYC—sarcoma	4.56e-05	0.00333	CbGpPWpGaD
Gemcitabine—Cough—Doxorubicin—sarcoma	4.56e-05	0.000399	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	4.53e-05	0.0033	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—NPM1—sarcoma	4.53e-05	0.0033	CbGpPWpGaD
Gemcitabine—Nervous system disorder—Epirubicin—sarcoma	4.52e-05	0.000396	CcSEcCtD
Gemcitabine—Thrombocytopenia—Epirubicin—sarcoma	4.51e-05	0.000395	CcSEcCtD
Gemcitabine—Hypertension—Doxorubicin—sarcoma	4.51e-05	0.000395	CcSEcCtD
Gemcitabine—Skin disorder—Epirubicin—sarcoma	4.47e-05	0.000392	CcSEcCtD
Gemcitabine—Hyperhidrosis—Epirubicin—sarcoma	4.45e-05	0.00039	CcSEcCtD
Gemcitabine—Myalgia—Doxorubicin—sarcoma	4.45e-05	0.00039	CcSEcCtD
Gemcitabine—Chest pain—Doxorubicin—sarcoma	4.45e-05	0.00039	CcSEcCtD
Gemcitabine—Arthralgia—Doxorubicin—sarcoma	4.45e-05	0.00039	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.42e-05	0.000387	CcSEcCtD
Gemcitabine—RRM2—Mitotic G1-G1/S phases—MYC—sarcoma	4.41e-05	0.00322	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	4.41e-05	0.00322	CbGpPWpGaD
Gemcitabine—Discomfort—Doxorubicin—sarcoma	4.39e-05	0.000385	CcSEcCtD
Gemcitabine—Anorexia—Epirubicin—sarcoma	4.39e-05	0.000385	CcSEcCtD
Gemcitabine—TYMS—Cell Cycle—NPM1—sarcoma	4.34e-05	0.00316	CbGpPWpGaD
Gemcitabine—Hypotension—Epirubicin—sarcoma	4.3e-05	0.000377	CcSEcCtD
Gemcitabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—sarcoma	4.29e-05	0.00313	CbGpPWpGaD
Gemcitabine—ABCB1—lymph node—sarcoma	4.28e-05	0.00072	CbGeAlD
Gemcitabine—Anaphylactic shock—Doxorubicin—sarcoma	4.26e-05	0.000373	CcSEcCtD
Gemcitabine—Oedema—Doxorubicin—sarcoma	4.26e-05	0.000373	CcSEcCtD
Gemcitabine—POLE—Mitotic G1-G1/S phases—MYC—sarcoma	4.24e-05	0.00309	CbGpPWpGaD
Gemcitabine—Infection—Doxorubicin—sarcoma	4.23e-05	0.000371	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Epirubicin—sarcoma	4.2e-05	0.000368	CcSEcCtD
Gemcitabine—Nervous system disorder—Doxorubicin—sarcoma	4.18e-05	0.000366	CcSEcCtD
Gemcitabine—Thrombocytopenia—Doxorubicin—sarcoma	4.17e-05	0.000366	CcSEcCtD
Gemcitabine—Insomnia—Epirubicin—sarcoma	4.17e-05	0.000365	CcSEcCtD
Gemcitabine—Skin disorder—Doxorubicin—sarcoma	4.14e-05	0.000363	CcSEcCtD
Gemcitabine—Paraesthesia—Epirubicin—sarcoma	4.14e-05	0.000362	CcSEcCtD
Gemcitabine—Hyperhidrosis—Doxorubicin—sarcoma	4.12e-05	0.000361	CcSEcCtD
Gemcitabine—TYMS—Retinoblastoma (RB) in Cancer—MYC—sarcoma	4.11e-05	0.003	CbGpPWpGaD
Gemcitabine—Dyspnoea—Epirubicin—sarcoma	4.11e-05	0.00036	CcSEcCtD
Gemcitabine—Somnolence—Epirubicin—sarcoma	4.09e-05	0.000359	CcSEcCtD
Gemcitabine—Anorexia—Doxorubicin—sarcoma	4.06e-05	0.000356	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	4.06e-05	0.00296	CbGpPWpGaD
Gemcitabine—POLA1—S Phase—CCND1—sarcoma	4.05e-05	0.00296	CbGpPWpGaD
Gemcitabine—Decreased appetite—Epirubicin—sarcoma	4e-05	0.000351	CcSEcCtD
Gemcitabine—Hypotension—Doxorubicin—sarcoma	3.98e-05	0.000349	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Epirubicin—sarcoma	3.98e-05	0.000348	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	3.97e-05	0.0029	CbGpPWpGaD
Gemcitabine—Fatigue—Epirubicin—sarcoma	3.97e-05	0.000348	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.96e-05	0.00289	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—ENO2—sarcoma	3.95e-05	0.00288	CbGpPWpGaD
Gemcitabine—Pain—Epirubicin—sarcoma	3.94e-05	0.000345	CcSEcCtD
Gemcitabine—Constipation—Epirubicin—sarcoma	3.94e-05	0.000345	CcSEcCtD
Gemcitabine—CDA—Metabolism—HBA1—sarcoma	3.92e-05	0.00286	CbGpPWpGaD
Gemcitabine—Musculoskeletal discomfort—Doxorubicin—sarcoma	3.88e-05	0.00034	CcSEcCtD
Gemcitabine—Insomnia—Doxorubicin—sarcoma	3.85e-05	0.000338	CcSEcCtD
Gemcitabine—Paraesthesia—Doxorubicin—sarcoma	3.83e-05	0.000335	CcSEcCtD
Gemcitabine—Dyspnoea—Doxorubicin—sarcoma	3.8e-05	0.000333	CcSEcCtD
Gemcitabine—Feeling abnormal—Epirubicin—sarcoma	3.8e-05	0.000333	CcSEcCtD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.79e-05	0.00276	CbGpPWpGaD
Gemcitabine—Somnolence—Doxorubicin—sarcoma	3.79e-05	0.000332	CcSEcCtD
Gemcitabine—POLA1—Mitotic G1-G1/S phases—CCND1—sarcoma	3.76e-05	0.00274	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	3.75e-05	0.00274	CbGpPWpGaD
Gemcitabine—Decreased appetite—Doxorubicin—sarcoma	3.7e-05	0.000325	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Doxorubicin—sarcoma	3.68e-05	0.000322	CcSEcCtD
Gemcitabine—Fatigue—Doxorubicin—sarcoma	3.67e-05	0.000322	CcSEcCtD
Gemcitabine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	3.65e-05	0.00266	CbGpPWpGaD
Gemcitabine—Pain—Doxorubicin—sarcoma	3.64e-05	0.000319	CcSEcCtD
Gemcitabine—Constipation—Doxorubicin—sarcoma	3.64e-05	0.000319	CcSEcCtD
Gemcitabine—Body temperature increased—Epirubicin—sarcoma	3.64e-05	0.000319	CcSEcCtD
Gemcitabine—TYMS—Circadian rythm related genes—CREB1—sarcoma	3.64e-05	0.00265	CbGpPWpGaD
Gemcitabine—TYMS—Mitotic G1-G1/S phases—CCND1—sarcoma	3.61e-05	0.00263	CbGpPWpGaD
Gemcitabine—POLA1—G1/S Transition—MYC—sarcoma	3.58e-05	0.00261	CbGpPWpGaD
Gemcitabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—sarcoma	3.52e-05	0.00257	CbGpPWpGaD
Gemcitabine—Feeling abnormal—Doxorubicin—sarcoma	3.51e-05	0.000308	CcSEcCtD
Gemcitabine—TYMS—G1/S Transition—MYC—sarcoma	3.43e-05	0.0025	CbGpPWpGaD
Gemcitabine—TYMS—Retinoblastoma (RB) in Cancer—TP53—sarcoma	3.38e-05	0.00246	CbGpPWpGaD
Gemcitabine—Body temperature increased—Doxorubicin—sarcoma	3.37e-05	0.000295	CcSEcCtD
Gemcitabine—CDA—Metabolism—PLCG1—sarcoma	3.35e-05	0.00244	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	3.33e-05	0.00243	CbGpPWpGaD
Gemcitabine—Asthenia—Epirubicin—sarcoma	3.3e-05	0.00029	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.27e-05	0.00239	CbGpPWpGaD
Gemcitabine—Pruritus—Epirubicin—sarcoma	3.26e-05	0.000286	CcSEcCtD
Gemcitabine—POLA1—S Phase—MYC—sarcoma	3.25e-05	0.00237	CbGpPWpGaD
Gemcitabine—ABCB1—Allograft Rejection—PDGFRA—sarcoma	3.21e-05	0.00234	CbGpPWpGaD
Gemcitabine—Diarrhoea—Epirubicin—sarcoma	3.15e-05	0.000276	CcSEcCtD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.14e-05	0.00229	CbGpPWpGaD
Gemcitabine—Asthenia—Doxorubicin—sarcoma	3.06e-05	0.000268	CcSEcCtD
Gemcitabine—POLA1—Mitotic G1-G1/S phases—MYC—sarcoma	3.02e-05	0.0022	CbGpPWpGaD
Gemcitabine—Pruritus—Doxorubicin—sarcoma	3.02e-05	0.000264	CcSEcCtD
Gemcitabine—RRM1—Metabolism—ENO2—sarcoma	2.99e-05	0.00218	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	2.99e-05	0.00218	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—HBA1—sarcoma	2.97e-05	0.00217	CbGpPWpGaD
Gemcitabine—Vomiting—Epirubicin—sarcoma	2.93e-05	0.000257	CcSEcCtD
Gemcitabine—Diarrhoea—Doxorubicin—sarcoma	2.92e-05	0.000256	CcSEcCtD
Gemcitabine—Rash—Epirubicin—sarcoma	2.9e-05	0.000255	CcSEcCtD
Gemcitabine—Dermatitis—Epirubicin—sarcoma	2.9e-05	0.000254	CcSEcCtD
Gemcitabine—TYMS—Mitotic G1-G1/S phases—MYC—sarcoma	2.89e-05	0.00211	CbGpPWpGaD
Gemcitabine—Headache—Epirubicin—sarcoma	2.89e-05	0.000253	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.85e-05	0.00208	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.85e-05	0.00207	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.82e-05	0.00206	CbGpPWpGaD
Gemcitabine—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	2.74e-05	0.002	CbGpPWpGaD
Gemcitabine—Nausea—Epirubicin—sarcoma	2.74e-05	0.00024	CcSEcCtD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.73e-05	0.00199	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.73e-05	0.00199	CbGpPWpGaD
Gemcitabine—Vomiting—Doxorubicin—sarcoma	2.71e-05	0.000237	CcSEcCtD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.71e-05	0.00197	CbGpPWpGaD
Gemcitabine—Rash—Doxorubicin—sarcoma	2.69e-05	0.000235	CcSEcCtD
Gemcitabine—Dermatitis—Doxorubicin—sarcoma	2.68e-05	0.000235	CcSEcCtD
Gemcitabine—Headache—Doxorubicin—sarcoma	2.67e-05	0.000234	CcSEcCtD
Gemcitabine—TYMS—Circadian rythm related genes—JUN—sarcoma	2.62e-05	0.00191	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.55e-05	0.00186	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—PLCG1—sarcoma	2.54e-05	0.00185	CbGpPWpGaD
Gemcitabine—Nausea—Doxorubicin—sarcoma	2.53e-05	0.000222	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.49e-05	0.00181	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—ENO2—sarcoma	2.46e-05	0.0018	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—ENO2—sarcoma	2.45e-05	0.00179	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—HBA1—sarcoma	2.45e-05	0.00179	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.45e-05	0.00178	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—HBA1—sarcoma	2.43e-05	0.00177	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.38e-05	0.00174	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—ENO2—sarcoma	2.3e-05	0.00168	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—HBA1—sarcoma	2.29e-05	0.00167	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.29e-05	0.00167	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.24e-05	0.00163	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.19e-05	0.0016	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.14e-05	0.00156	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.11e-05	0.00154	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—PLCG1—sarcoma	2.09e-05	0.00152	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—PLCG1—sarcoma	2.08e-05	0.00151	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—MDM2—sarcoma	2.07e-05	0.00151	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—MDM2—sarcoma	2.06e-05	0.0015	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.02e-05	0.00148	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle, Mitotic—CCND1—sarcoma	2.02e-05	0.00147	CbGpPWpGaD
Gemcitabine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	2.01e-05	0.00146	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—CCND1—sarcoma	2.01e-05	0.00146	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—MDM2—sarcoma	1.99e-05	0.00145	CbGpPWpGaD
Gemcitabine—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	1.97e-05	0.00144	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—PLCG1—sarcoma	1.95e-05	0.00142	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle, Mitotic—CCND1—sarcoma	1.94e-05	0.00141	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.88e-05	0.00137	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—CCND1—sarcoma	1.8e-05	0.00132	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.8e-05	0.00131	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—CCND1—sarcoma	1.79e-05	0.00131	CbGpPWpGaD
Gemcitabine—ABCB1—Allograft Rejection—IL2—sarcoma	1.75e-05	0.00128	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—CCND1—sarcoma	1.73e-05	0.00126	CbGpPWpGaD
Gemcitabine—TYMS—Circadian rythm related genes—TP53—sarcoma	1.73e-05	0.00126	CbGpPWpGaD
Gemcitabine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	1.72e-05	0.00125	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle, Mitotic—MYC—sarcoma	1.62e-05	0.00118	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—ENO2—sarcoma	1.61e-05	0.00118	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—MYC—sarcoma	1.61e-05	0.00117	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—HBA1—sarcoma	1.6e-05	0.00117	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	1.58e-05	0.00116	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle, Mitotic—MYC—sarcoma	1.55e-05	0.00113	CbGpPWpGaD
Gemcitabine—ABCB1—Allograft Rejection—VEGFA—sarcoma	1.49e-05	0.00109	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—MYC—sarcoma	1.45e-05	0.00106	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—MYC—sarcoma	1.44e-05	0.00105	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—MDM2—sarcoma	1.42e-05	0.00103	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—MYC—sarcoma	1.39e-05	0.00101	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—CCND1—sarcoma	1.38e-05	0.00101	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—PLCG1—sarcoma	1.37e-05	0.000999	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—MDM2—sarcoma	1.36e-05	0.00099	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—CCND1—sarcoma	1.32e-05	0.000964	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—CCND1—sarcoma	1.23e-05	0.0009	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—TP53—sarcoma	1.19e-05	0.000867	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—CCND1—sarcoma	1.18e-05	0.000862	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—TP53—sarcoma	1.18e-05	0.000862	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	1.17e-05	0.000853	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—TP53—sarcoma	1.14e-05	0.000832	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—MYC—sarcoma	1.11e-05	0.000807	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—MYC—sarcoma	1.06e-05	0.000774	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—MYC—sarcoma	9.9e-06	0.000722	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	9.68e-06	0.000706	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—MYC—sarcoma	9.48e-06	0.000692	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	8.43e-06	0.000615	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	8.41e-06	0.000613	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	8.35e-06	0.000609	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—TP53—sarcoma	8.13e-06	0.000593	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—TP53—sarcoma	7.79e-06	0.000568	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	7.54e-06	0.00055	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	7.35e-06	0.000536	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	6.76e-06	0.000493	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	6.61e-06	0.000482	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	6.25e-06	0.000456	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	5.55e-06	0.000405	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—ENO2—sarcoma	4.98e-06	0.000363	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—HBA1—sarcoma	4.95e-06	0.000361	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—PLCG1—sarcoma	4.23e-06	0.000308	CbGpPWpGaD
